01 / 05
MED
TECH
001 — Oxotoxo / Medical Technology

Precision. Innovation.
Impact.

We develop next-generation medical devices addressing critical unmet needs. Our work sits at the intersection of material science, clinical practice, and engineering precision.

EST. 2024 — MEDICAL TECHNOLOGY PATENT PENDING
ABOUT
002 — About

Building the
devices
of tomorrow.

Oxotoxo is a medical technology company developing a portfolio of patentable devices that address unmet clinical needs across elderly care, diagnostics, and interventional medicine.

We identify problems where existing solutions are inadequate — and develop devices that are meaningfully better. We build on proven materials and established clinical pathways, reducing regulatory risk while maximising clinical impact.

Currently in active prototype and patent development phase.

ACTIVE DEVELOPMENT DK / INTERNATIONAL
003
003 — Focus Areas

Three clinical
challenges.

01_
Elderly care
Demographic pressure demands innovation in care infrastructure. We are developing a device that addresses one of the most fundamental challenges in patient care environments.
02_
Clinical precision
Minimising patient discomfort through material and engineering innovation. Our work builds on established clinical materials with a fundamentally different approach.
03_
Diagnostics
Our most advanced development — a diagnostic device in active prototype phase delivering a meaningfully different clinical outcome through a novel configuration.
THREE PRODUCT TRACKS PROTOTYPE PHASE
HOW
004 — Approach

How we
work.

01_
Patent-first
We secure intellectual property before commercialisation. Core innovations are protected before external engagement.
02_
Build on proven
We reuse approved materials and established clinical pathways — reducing regulatory risk and time to market.
03_
Partnership model
We seek specialist partners with complementary expertise in manufacturing, clinical validation, and distribution.
04_
Selective disclosure
We are deliberate about what we share. If you are reading this, we are open to the right conversation.
METHODOLOGY IP PROTECTED
CON
TACT
005 — Contact

The right
conversation.

We are not seeking public attention. If you have relevant expertise or a specific interest in our work — we would like to hear from you.

Thank you.
We will be in touch if there is a fit.
OXOTOXO APS PART OF ØSTERGADE KAPITAL A/S
OXOTOXO MEDICAL TECHNOLOGY